Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns positive
Q1 FY2026 other income / expenses was $1.34M, compared with -$775K a year earlier. Trailing-twelve-month other income / expenses was $3.8M. Over 3 fiscal years it compounded at -3.5% a year.
Context
- Other income / expenses amounted to 12.8% of revenue in FY2025, down 53.2 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near $1.34M or moves back toward the trailing-twelve-month quarterly average of $950K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 1.68M USD
- Year-over-year change
- -74.8%
- 4-year CAGR
- +186.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.68M | -74.8% |
| FY2024 | 2024-12-31 | 6.67M | +287.0% |
| FY2023 | 2023-12-31 | 1.72M | -8.1% |
| FY2022 | 2022-12-31 | 1.87M | +7392.0% |
| FY2021 | 2021-12-31 | 25K | — |
Other Income / Expenses vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +106.4% is the 2nd highest of 10, against a peer median of -24.4%.
- Other income / expenses amounts to 21.6% of revenue for TNXP, versus a peer median of 172.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $40.74M USD | -24.4% | — | 3552.1% | |
| LTM Mar 2026 | $16.38M USD | -21.0% | +49.6% | — | |
| LTM Mar 2026 | $9.52M USD | -61.3% | -24.7% | 150.7% | |
| LTM Mar 2026 | $8.36M USD | -85.9% | +333.6% | — | |
| FY2025 | €4.25M EUR | +101.9% | — | 152.4% | |
| LTM Mar 2026 | $3.8M USD | +106.4% | -3.5% | 21.6% | |
| LTM Mar 2026 | $2.53M USD | +109.2% | +414.8% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$2.61M USD | +55.1% | — | — |
| LTM Mar 2026 | -$3.08M USD | -1482.5% | — | 172.8% | |
| LTM Mar 2026 | -$5.41M USD | -104.4% | — | 9176.3% | |
| Peer median (excluding TNXP) | — | -24.4% | +191.6% | 172.8% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.